Charles River Laboratories Intl (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Sales | 4,129,409 | 3,976,060 | 3,540,160 | 2,923,933 | 2,621,226 |
| Cost of Goods | 2,626,853 | 2,513,409 | 2,205,522 | 1,850,392 | 1,662,915 |
| Gross Profit | 1,502,556 | 1,462,651 | 1,334,638 | 1,073,541 | 958,311 |
| Operating Expenses | 886,148 | 812,085 | 745,298 | 641,204 | 608,075 |
| Operating Income | 617,261 | 650,975 | 589,862 | 432,729 | 351,151 |
| Interest Expense | 136,710 | 59,291 | 73,910 | 86,433 | 60,882 |
| Other Income | 100,733 | 31,303 | -35,242 | 100,818 | 13,815 |
| Pre-tax Income | 581,284 | 622,987 | 480,710 | 447,114 | 304,084 |
| Income Tax | 100,914 | 130,379 | 81,873 | 81,808 | 50,023 |
| Net Income Continuous | 480,370 | 492,608 | 398,837 | 365,306 | 254,061 |
| Minority Interests | 5,746 | 6,382 | 7,855 | 1,002 | 2,042 |
| Net Income | $474,624 | $486,226 | $390,982 | $364,304 | $252,019 |
| EPS Basic Total Ops | 9.27 | 9.57 | 7.77 | 7.35 | 5.17 |
| EPS Basic Continuous Ops | 9.38 | 9.69 | 7.93 | 7.37 | 5.21 |
| EPS Diluted Total Ops | 9.22 | 9.48 | 7.60 | 7.20 | 5.07 |
| EPS Diluted Continuous Ops | 9.34 | 9.60 | 7.76 | 7.22 | 5.11 |
| EPS Diluted Before Non-Recurring Items | 10.67 | 11.12 | 10.32 | 8.13 | 6.73 |
| EBITDA(a) | $931,385 | $954,845 | $855,402 | $667,653 | $549,246 |